arginine has been researched along with Kahler Disease in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Liu, M; Ouyang, J; Xia, T; Xu, P; Zhao, Q | 1 |
| Croci, E; Dentali, F; Giorgi-Pierfranceschi, M; Mumoli, N; Scarpioni, R | 1 |
| Barwick, BG; Boise, LH; Cheng, X; Hashimoto, H; Lonial, S; Vertino, PM; Wang, D; Zhang, X | 1 |
| Bloem, AC; de Kort, RA; Lokhorst, HM; Mutis, T; Spaapen, RM; van den Oudenalder, K; van Elk, M | 1 |
| Frondoza, CG; Goble, JC; Humphrey, RL; Trivedi, SM | 1 |
| Massie, B; Mercille, S | 1 |
| Matsuura, K; Sinohara, H | 1 |
| Das, UN; Sravan Kumar, G | 1 |
| Baek, K; Chung, HY; Jang, YJ; Kim, YT; Park, JS | 1 |
| Pryme, IF | 1 |
| Engstrom, SK; Mansy, S; Peticolas, WL | 1 |
| Hata, H; Matsuno, F; Matsuzaki, H; Okazaki, K; Takatsuki, K; Yoshida, M | 1 |
| Ballieux, RE; De Jong, JG; De Vijlder, MM; Easley, CW; Zegers, BJ | 1 |
| Tischendorf, FW; Tischendorf, MM | 1 |
| Morell, A; Terry, WD; Waldmann, TA | 1 |
| Aviv, A; Haddid, Y; Lavi, N; Rabani, H; Shalata, A; Suriu, C; Tadmor, T; Ziv, M | 1 |
| Bettencourt, MJ; Capela, T; Russo, P; Tomé, AL | 1 |
| Alici, E; Borg Bruchfeld, J; Gahrton, G; Gran, C; Lund, J; Månsson, R; Nahi, H; Uttervall, K; Wålinder, G | 1 |
| Kumano, K; Kurokawa, M; Nakamura, F; Tsukamoto, A; Yamazaki, S; Yoshiki, Y | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Carbone, A; Franchin, G; Galligioni, E; Grigoletto, E; Tirelli, U; Trovo, MG; Tumolo, S; Veronesi, A; Volpe, R | 1 |
| Liu, S; Zhu, B | 1 |
| Caporale, R; Ciolli, S; Ferrini, PR; Leoni, F; Salti, F | 1 |
| Ciolli, S; Ferrini, PR; Leoni, F; Salti, F; Teodori, P | 1 |
| Brema, F; Carbone, A; Grigoletto, E; Tirelli, U; Veronesi, A; Volpe, R; Zagonei, V | 1 |
2 trial(s) available for arginine and Kahler Disease
| Article | Year |
|---|---|
Continuous-infusion cyclophosphamide in combination with teniposide and dexamethasone in refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Survival Rate; Teniposide | 1992 |
Phase II study of teniposide (VM-26) in multiple myeloma.
Topics: Adult; Aged; Blood Cell Count; Blood Proteins; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Immunoglobulins; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Multiple Myeloma; Podophyllotoxin; Teniposide | 1985 |
23 other study(ies) available for arginine and Kahler Disease
| Article | Year |
|---|---|
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Topics: Animals; Arginine; Caspase 1; Cell Line, Tumor; Cell Membrane; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Male; Methylation; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Multiple Myeloma; Multivariate Analysis; Promoter Regions, Genetic; Protein-Arginine N-Methyltransferases; Pyroptosis; RNA, Messenger; Survival Analysis; Treatment Outcome; Up-Regulation | 2021 |
Argatroban for Treatment of Heparin-Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Dalteparin; Female; Humans; Multiple Myeloma; Partial Thromboplastin Time; Pipecolic Acids; Renal Dialysis; Sulfonamides; Thrombocytopenia; Venous Thrombosis | 2016 |
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.
Topics: Arginine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; CpG Islands; Cytosine; DNA; E-Box Elements; Epigenesis, Genetic; Multiple Myeloma; Mutation; Protein Binding; Protein Conformation; Repressor Proteins | 2017 |
Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis.
Topics: Alleles; Arginine; CD4-Positive T-Lymphocytes; Genome; Genotype; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Membrane Transport Proteins; Minor Histocompatibility Antigens; Models, Genetic; Multiple Myeloma; Peptides; Phenotype; Polymorphism, Single Nucleotide; Reduced Folate Carrier Protein | 2009 |
Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man.
Topics: Aged; Animals; Arginine; Carbon Radioisotopes; Feces; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Middle Aged; Multiple Myeloma; Protein Biosynthesis; Radiation Dosage; Radionuclide Imaging; Rats; Time Factors; Tissue Distribution | 1980 |
Induction of apoptosis in oxygen-deprived cultures of hybridoma cells.
Topics: ABO Blood-Group System; Animals; Antibodies, Monoclonal; Apoptosis; Arginine; Biotechnology; Cell Division; Cell Hypoxia; Culture Techniques; Cystine; Glucose; Glutamine; Hybridomas; Immunoglobulin M; Kinetics; Lactates; Mice; Models, Theoretical; Multiple Myeloma; Time Factors; Tumor Cells, Cultured | 1994 |
Catalytic cleavage of vasopressin by human Bence Jones proteins at the arginylglycinamide bond.
Topics: Arginine; Bence Jones Protein; Catalysis; Glycine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Multiple Myeloma; Vasopressins | 1996 |
Cytotoxic action of alpha-linolenic and eicosapentaenoic acids on myeloma cells in vitro.
Topics: alpha-Linolenic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arginine; Calmodulin; Cell Division; Cell Survival; Cyclooxygenase Inhibitors; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Glutathione; Indomethacin; Lipoxygenase Inhibitors; Mice; Multiple Myeloma; omega-N-Methylarginine; Prostaglandins; Tumor Cells, Cultured; Vitamin E | 1997 |
Primary structures and chain dominance of anti-DNA antibodies.
Topics: Amino Acid Sequence; Animals; Antibodies, Antinuclear; Antibodies, Monoclonal; Arginine; Cell Fusion; Complementarity Determining Regions; Cross-Linking Reagents; DNA Primers; Immunodominant Epitopes; Immunoglobulin Variable Region; Mice; Mice, Inbred MRL lpr; Molecular Sequence Data; Multiple Myeloma; Spleen; Tumor Cells, Cultured; Ultraviolet Rays | 2001 |
The effects of orally administered L-arginine HCl on the development of myeloma tumors in BABL/C mice following the injection of single cell suspensions, cell aggregates or tumor fragments; and on the growth of two ascites tumour cell lines.
Topics: Administration, Oral; Animals; Arginine; Carcinoma, Krebs 2; Cell Aggregation; Cell Communication; Cell Count; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Multiple Myeloma; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation, Isogeneic | 1978 |
Laser Raman identification of an interaction site on DNA for arginine containing histones in chromatin.
Topics: Animals; Arginine; Binding Sites; Cattle; Chromatin; DNA; DNA, Neoplasm; Histones; Lasers; Mice; Multiple Myeloma; Nucleic Acid Conformation; Protein Binding; Protein Conformation; Scattering, Radiation; Spectrum Analysis; Thymus Gland | 1976 |
Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia.
Topics: Ammonia; Arginine; Cell Line; Female; Glutamine; Humans; Immunoglobulin A; Immunoglobulin kappa-Chains; Middle Aged; Multiple Myeloma; Tumor Cells, Cultured | 1992 |
Studies on Fd-fragments of human immunoglobulins. I. A Comparative peptide mapping study on L-chains, Fab- and Fd-fragments of G-myeloma proteins.
Topics: Amino Acids; Arginine; Electrophoresis; Genes; Globulins; Humans; Immunoglobulins; Multiple Myeloma; Neoplasm Proteins; Peptides; Staining and Labeling; Trypsin | 1970 |
Markers of the variable and constant region of human lambda immunoglobulin chains.
Topics: Alleles; Amino Acid Sequence; Antigens; Arginine; Bence Jones Protein; Blood Group Antigens; Epitopes; Formates; Genes; Genetic Code; Germ Cells; Humans; Immune Sera; Immunodiffusion; Immunoglobulin G; Immunoglobulins; Lysine; Multiple Myeloma; Peptides; Trypsin; Waldenstrom Macroglobulinemia | 1970 |
Metabolic properties of IgG subclasses in man.
Topics: Adult; Aged; Arginine; Carbon Isotopes; Female; Guanidines; Humans; Immunoelectrophoresis; Immunoglobulin G; Iodine Isotopes; Male; Middle Aged; Multiple Myeloma | 1970 |
Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Gene Amplification; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Humans; Immunoglobulin Constant Regions; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Israel; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Progression-Free Survival; Retrospective Studies; Teniposide; Treatment Outcome | 2020 |
Anorectal involvement in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Prognosis; Retroperitoneal Neoplasms; Sigmoidoscopy; Teniposide | 2017 |
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Proportional Hazards Models; Survival Analysis; Teniposide; Treatment Outcome | 2019 |
The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Cyclophosphamide; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pleural Effusion, Malignant; Salvage Therapy; Teniposide | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
VM26 in malignant hematological diseases. A phase II study.
Topics: Drug Evaluation; Hodgkin Disease; Humans; Leukemia, Lymphoid; Lymphoma; Multiple Myeloma; Podophyllotoxin; Teniposide | 1982 |
[Teniposide, cyclophosphamide and dexamethasone combination treatment for stage III multiple myeloma: a report of 21 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Teniposide | 1997 |
Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Resistance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Teniposide | 1991 |